Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The primary hyperoxalurias are rare disorders of glyoxylate metabolism. Accurate diagnosis is essential for therapeutic and management strategies. We conducted a molecular study on patients suffering from recurrent calcium-oxalate stones and nephrocalcinosis and screened primary hyperoxaluria causing genes in a large cohort of early-onset cases. Disease-associated pathogenic-variants were defined as missense, nonsense, frameshift-indels, and splice-site variants with a reported minor allele frequency <1% in controls. We found pathogenic-variants in 34% of the cases. Variants in the AGXT gene causing PH-I were identified in 81% of the mutation positive cases. PH-II-associated variants in the GRHPR gene are found in 15% of the pediatric PH-positive population. Only 3% of the PH-positive cases have pathogenic-variants in the HOGA1 gene, responsible to cause PH-III. A population-specific AGXT gene variant c.1049G>A; p.Gly350Asp accounts for 22% of the PH-I-positive patients. Pathogenicity of the identified variants was evaluated by in-silico tools and ACMG guidelines. We have devised a rapid and low-cost approach for the screening of PH by using targeted-NGS highlighting the importance of an accurate and cost-effective screening platform. This is the largest study in Pakistani pediatric patients from South-Asian region that also expands the mutation spectrum of the three known genes.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cge.14240DOI Listing

Publication Analysis

Top Keywords

primary hyperoxaluria
8
causing genes
8
hyperoxaluria comprehensive
4
comprehensive mutation
4
mutation screening
4
screening disease
4
disease causing
4
genes spectrum
4
spectrum disease-associated
4
disease-associated pathogenic
4

Similar Publications

Background: Primary hyperoxaluria (PH), a rare autosomal recessive disease of oxalate accumulation in the kidneys, is caused by biallelic pathogenic changes in three known genes: (PH1), (PH2) and (PH3).

Methods: To better understand the overall risk of developing clinical PH, we manually curated and classified PH genetic variants and calculated the estimated genetic prevalence overall and in five ethnic subpopulations using allelic frequencies from the population Genome Aggregation Database (gnomAD version 2.1.

View Article and Find Full Text PDF

Liver Transplantation in Childhood: A 2-Year Single Center Experience.

Transplant Proc

August 2025

Florya VM Medical Park Application and Research Hospital, Organ Transplantation Center, Dr. Istanbul Aydın University, Istanbul, Turkey.

Objective: Liver transplantation is currently the most treatment for fulminant hepatitis, end-stage liver failure, hepatocellular carcinoma, and liver-originated metabolic diseases in children. With technological advances, improvements in surgical techniques and immunosuppressive therapy protocols have increased 1-year survival rates to 80%-90%. Our center successfully performs both living donor and cadaveric liver transplants in children.

View Article and Find Full Text PDF

Introduction: The incidence of pediatric nephrolithiasis has been increasing, and the role of genetic factors has garnered attention in recent years. This study aimed to explore the genetic basis underlying pediatric nephrolithiasis in Chinese population.

Methods: Whole exome sequencing (WES) was conducted in a consecutive cohort of 456 children over a 11-year period.

View Article and Find Full Text PDF

The evolving role of liver transplantation as enzyme replacement therapy in the era of RNA nanotherapies.

Am J Transplant

August 2025

Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; Ajmera Transplant Center, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Solid organ transplantation (SOT) is a treatment for monogenic diseases like transthyretin amyloidosis (ATTR) and primary hyperoxaluria (PH). The advent of RNA nanotherapy has introduced new disease-modifying options for ATTR and PH. We examined the prevalence, clinical characteristics, and outcomes of SOT waitlisted candidates (due to ATTR/PH) pre-US Food and Drug Administration (US FDA) and post-US FDA approval of patisiran and lumasiran, respectively.

View Article and Find Full Text PDF

Background: Urinary stone disease with a clear genetic cause, monogenic stone disease (MSD), is increasingly recognized as a significant proportion of the total population. When MSD is suspected, genetic testing provides a firm diagnosis that can alter management and treatment. Here we present testing results from a large cohort with suspected MSD.

View Article and Find Full Text PDF